{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T05:16:20Z","timestamp":1765516580241,"version":"3.48.0"},"reference-count":13,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T00:00:00Z","timestamp":1765497600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To deepen understanding of the correlation between intracranial tumor and serum myelin oligodendrocyte glycoprotein immunoglobulin G (MOG-IgG) positivity, emphasizing the importance of avoiding misdiagnosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We report a case involving a 24-year-old Chinese male whose clinical manifestations included slowed responsiveness, dysarthria, and right-sided limb weakness. Beyond serum MOG-IgG positivity, the nature of the central nervous system lesion was further evaluated based on therapeutic response and multimodal imaging.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The patient exhibited serum MOG-IgG positivity with an upward trend in titers. Immunotherapy failed to provide sustained and effective control of disease progression. Integrating the therapeutic response and characteristic imaging changes, a final diagnosis of malignant intracranial tumor was reached. Following diagnosis, he declined further oncologic therapy and died one month later due to a pulmonary infection.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Serum MOG-IgG positivity and an initial response to immunotherapy may be misleading and contribute to diagnostic confusion with inflammatory demyelinating disorders. In atypical or treatment-refractory MOG antibody-associated disease, clinicians should remain vigilant for the possibility of a central nervous system space-occupying lesion.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2025.1673927","type":"journal-article","created":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T05:15:00Z","timestamp":1765516500000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case report of intracranial tumor with serum MOG-IgG positivity"],"prefix":"10.3389","volume":"16","author":[{"given":"Zhuo","family":"Min","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lingru","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yulai","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lili","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,12,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.17712\/nsj.2024.3.20230111","article-title":"Tumefactive demyelinating lesions: A literature review of recent findings","volume":"29","author":"Al Malik","year":"2024","journal-title":"Neurosci (Riyadh)"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(22)00431-8","article-title":"Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria","volume":"22","author":"Banwell","year":"2023","journal-title":"Lancet Neurol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.885218","article-title":"Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): A review of clinical and MRI features, diagnosis, and management","volume":"13","author":"Sechi","year":"2022","journal-title":"Front Neurol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000206820","article-title":"Tumefactive demyelination in MOG ab-associated disease, multiple sclerosis, and AQP-4-igG-positive neuromyelitis optica spectrum disorder","volume":"100","author":"Cacciaguerra","year":"2023","journal-title":"Neurology"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1111\/j.1552-6569.2007.00231.x","article-title":"Central nervous system lymphoma characterization by diffusion-weighted imaging and MR spectroscopy","volume":"18","author":"Zacharia","year":"2008","journal-title":"J Neuroimaging"},{"key":"B6","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.msard.2018.08.025","article-title":"Proton magnetic resonance spectroscopy differentiates tumefactive demyelinating lesions from gliomas","volume":"26","author":"Ikeguchi","year":"2018","journal-title":"Mult Scler Relat Disord"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1177\/1971400918783058","article-title":"Arterial spin labeling perfusion: Prospective MR imaging in differentiating neoplastic from non-neoplastic intra-axial brain lesions","volume":"31","author":"Soni","year":"2018","journal-title":"Neuroradiol J"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000001014","article-title":"Updated diagnostic criteria for paraneoplastic neurologic syndromes","volume":"8","author":"Graus","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.1193211","article-title":"Investigating the association between neoplasms and MOG antibody-associated disease","volume":"14","author":"Trentinaglia","year":"2023","journal-title":"Front Neurol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"577743","DOI":"10.1016\/j.jneuroim.2021.577743","article-title":"Myelin oligodendrocyte glycoprotein (MOG) antibodies in a patient with glioblastoma: Red flags for false positivity","volume":"361","author":"Amin","year":"2021","journal-title":"J Neuroimmunol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"577823","DOI":"10.1016\/j.jneuroim.2022.577823","article-title":"A tumefactive anti-MOG antibody associated disorder heralding central nervous system B-cell lymphoma: Case report on diagnostic challenge","volume":"365","author":"Uzura","year":"2022","journal-title":"J Neuroimmunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-023-06919-1","article-title":"Myelin oligodendrocyte glycoprotein antibody-associated disease preceding primary central nervous system lymphoma: causality or coincidence","volume":"44","author":"Cai","year":"2023","journal-title":"Neurol Sci"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200275","article-title":"MOG CNS autoimmunity and MOGAD","volume":"11","author":"Moseley","year":"2024","journal-title":"Neurol Neuroimmunol Neuroinflamm"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1673927\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T05:15:00Z","timestamp":1765516500000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1673927\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,12]]},"references-count":13,"alternative-id":["10.3389\/fimmu.2025.1673927"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1673927","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,12]]},"article-number":"1673927"}}